Back

prof. dr. H.M. (Helena) Verkooijen

prof. dr. H.M. (Helena) Verkooijen

Full Professor
prof. dr. H.M. (Helena) Verkooijen
  • Clinical Trial Office

Research Programs

Strategic Program Cancer

Biography

Biography

Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.

Leader (PI) of several international (H2020) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member.

Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).

I lead two international consortia (one H2020 European, one transatlantic) and collaborate closely with (international) academic and industry partners. I am regularly invited as speaker at international conferences, educational sessions and consortium meetings, and as panelist at meetings/debates of professional organizations. I serve as a member in several scientific advisory boards and expert committees.

I am Strategic Advisor for 'NTvG Gezonde Zorg', a campaign of the Dutch Journal of Medicine (Nederlands Tijdschrift voor Geneeskunde). This campaign contributes to ensuring sustainability and affordability of health care in the Netherlands by exposing the harms of medicalisation (overdiagnosis and overtreatment) and explicitly demonstrating the power of (primary) prevention. 

Side Activities

 

  • PI of transatlantic MOMENTUM study, funded by Elekta.
  • Board Member Dutch Breast Cancer Research Group (Borstkanker Onderzoek Groep, BOOG)
  • Member Scientific Advisory Board Dutch Expert Centre for Screening
  • Board Member J.M. Fentener van Vlissingen Fonds
  • Member Scientific Advisory Board Dutch Prospective Colorectal Cancer Cohort (PLCRC)
  • Member Expert Committee Value-Based Health Care Breast Cancer (NFU)

Research Output (346)

Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation

Vasmel Jeanine E., Groot Koerkamp Maureen L., Mandija Stefano, Veldhuis Wouter B., Moman Maaike R., Froeling Martijn, van der Velden Bas H.M., Charaghvandi Ramona K., Vreuls Celien P.H., van Diest Paul J., van Leeuwen A. M.Gijs, van Gorp Joost, Philippens Marielle E.P., van Asselen Bram, Lagendijk Jan J.W., Verkooijen Helena M., van den Bongard H. J.G.Desirée, Houweling Antonetta C. 1 Mar 2022, In: Advances in Radiation Oncology. 7 , p. 1-11

AI-Based Radiation Dose Quantification for Estimation of Heart Disease Risk in Breast Cancer Survivors After Radiation Therapy

van Velzen Sanne G M, Gal Roxanne, Teske Arco J, van der Leij Femke, van den Bongard Desirée H J G, Viergever Max A, Verkooijen Helena M, Išgum Ivana 1 Mar 2022, In: International Journal of Radiation Oncology Biology Physics. 112 , p. 621-632 12 p.

AI-Based Quantification of Planned Radiation Therapy Dose to Cardiac Structures and Coronary Arteries in Patients With Breast Cancer

van Velzen Sanne G M, Bruns Steffen, Wolterink Jelmer M, Leiner Tim, Viergever Max A, Verkooijen Helena M, Išgum Ivana 1 Mar 2022, In: International Journal of Radiation Oncology Biology Physics. 112 , p. 611-620 10 p.

Impact of Dose-Escalated Chemoradiation on Quality of Life in Patients With Locally Advanced Rectal Cancer:2-Year Follow-Up of the Randomized RECTAL-BOOST Trial

Verweij Maaike E., Hoendervangers Sieske, Couwenberg Alice M., Burbach J. P.Maarten, Berbee Maaike, Buijsen Jeroen, Roodhart Jeanine, Reerink Onne, Pronk Apollo, Consten Esther C.J., Smits Anke B., Heikens Joost T., van Grevenstein W. Helma M.U., Intven Martijn P.W., Verkooijen H. Lenny M. 1 Mar 2022, In: International Journal of Radiation Oncology Biology Physics. 112 , p. 694-703 10 p.

Quality of Life After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases

Pielkenrood Bart J, Gal Roxanne, Kasperts Nicolien, Verhoeff Joost Jc, Bartels Marcia Mtj, Seravalli Enrica, van der Linden Yvette M, Monninkhof Evelyn M, Verlaan Jorrit-Jan, van der Velden Joanne M, Verkooijen Helena M 10 Jan 2022, In: International Journal of Radiation Oncology Biology Physics. 112 , p. 1203-1215 13 p.

Interrater agreement of contouring of the neurovascular bundles and internal pudendal arteries in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer

Teunissen F. R., Wortel R. C., Wessels F. J., Claes A., van de Pol S. M.G., Rasing M. J.A., Meijer R. P., van Melick H. H.E., de Boer J. C.J., Verkooijen H. M., van der Voort van Zyp J. R.N. Jan 2022, In: Clinical and translational radiation oncology. 32 , p. 29-34 6 p.

Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial

Groen Veerle H, van Schie Marcel, Zuithoff Nicolaas P A, Monninkhof Evelyn M, Kunze-Busch Martina, de Boer Johannes C J, van der Voort van Zijp Jochem, Pos Floris J, Smeenk Robert Jan, Haustermans Karin, Isebaert Sofie, Draulans Cédric, Depuydt Tom, Verkooijen Helena M, van der Heide Uulke A, Kerkmeijer Linda G W 28 Dec 2021, In: Radiotherapy & Oncology. 167 , p. 127-132 6 p.

Coronary artery calcifications on breast cancer radiotherapy planning CT scans and cardiovascular risk:What do patients want to know?

Gal Roxanne, Gregorowitsch Madelijn L., Emaus Marleen J., Blezer Erwin LA, van der Leij Femke, van Velzen Sanne GM, van Tol-Geerdink Julia J., Išgum Ivana, Verkooijen Helena M. Dec 2021, In: International Journal of Cardiology: Cardiovascular Risk and Prevention. 11

Expectations of treatment outcomes in patients with spinal metastases; what do we tell our patients?:A qualitative study

Versteeg Anne L, Gal Roxanne, Charest-Morin Raphaele, Verlaan Jorrit-Jan, Wessels Hester, Fisher Charles G, Verkooijen Helena M Dec 2021, In: BMC Cancer. 21 , p. 1-8

The Prospective Dutch Colorectal Cancer (PLCRC) cohort:real-world data facilitating research and clinical care

Derksen Jeroen W G, Vink Geraldine R, Elferink Marloes A G, Roodhart Jeanine M L, Verkooijen Helena M, van Grevenstein Wilhelmina M U, Siersema Peter D, May Anne M, Koopman Miriam, Dec 2021, In: Scientific Reports. 11 , p. 1-12

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet